Mixed Support For ABPI's UK Price Scheme Proposals
Executive Summary
The UK pharma industry body has set out bold proposals for a new drug pricing agreement from 2024, but not everyone is convinced. Generics companies are pressing for more of a say in the negotiations, while patient groups want to know more about how the deal would help improve access to medicines.
You may also be interested in...
ABPI’s 6.88% Rebate Proposal ‘Completely Unaffordable,’ Says UK Health Dept
Plans for a new kind of drug pricing scheme put forward by the UK ABPI are intended to put the life sciences sector “back on the path for future growth,” the association says.
What Role Is There for Patients In Managed Access Deals?
Market access deals can make or break routine access to new treatments. So what happens when patient-centricity and deal-making meet? Leela Barham looks at the experience in England.
The People Who Will Shape The UK’s New Drug Pricing Scheme
With talks on the next UK voluntary pricing scheme now well under way, the Pink Sheet looks at the industry and government negotiators who will be thrashing out the details in the coming months.